04:26 PM EDT, 06/09/2025 (MT Newswires) -- Keros Therapeutics ( KROS ) shareholder, ADAR1 Capital Management, said Monday that the company should return $475 million to shareholders, $100 million more than what the company has committed, via a special dividend by the end of Q3.

ADAR1 said the company's board should ensure that shareholders directly capture the potential cash flow from the Takeda Pharmaceutical (TAK) partnership through a contingent value right or similar mechanism, which should be implemented no later than year-end.

ADAR1's statement follows the company's 2025 annual shareholders meeting. Keros stockholders elected Mary Ann Gray, Ran Nussbaum and Alpna Seth as directors, a regulatory filing shows.

ADAR1 said it had decided to withhold votes for directors -- Mary Ann Gray and Alpna Seth -- at the annual meeting. ADAR1 said these directors received 34% and 37% votes, respectively, reelecting "a substantial loss of stockholder confidence in the board."

ADAR1 mentioned that it "will not hesitate to hold [the company] accountable, including by nominating new directors for election at the 2026 annual meeting," provided the company fails to change its strategy.

Keros Therapeutics ( KROS ) didn't immediately respond to a request for comment from MT Newswires.